WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that Douglas M. Fambrough, PhD, the Company’s President and CEO, will present at the 9th Annual JMP Securities Healthcare Conference on June 24 2014, at 1:00 PM ET in New York, NY.
A live webcast of the presentation can be accessed by visiting "Events & Presentations" in the Investors and Media section on the Company's website at www.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.
About Dicerna Pharmaceuticals, Inc.
Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using its proprietary RNA interference (RNAi) technology platform to build a broad pipeline in these therapeutic areas and intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners.